PTK2B is highly expressed in glioma DBTRG-05MG cells harboring BRAFV600E mutation, and its knockdown induces severe cell death. To explore the anti-tumor mechanism of targeting PTK2B and elucidate its therapeutical potential, we performed proteomics of DBTRG-05MG cells with or without PTK2B knockdown.